Barinthus Bio Q2 net loss $21.1M ($0.52/share); cash $87.8M, runway into 2027

Barinthus Biotherapeutics plc.

2025-Q2 EPS reported -$1.01

Cash, cash equivalents & restricted cash $87.8M at June 30, 2025, down $12.8M from Q1.
Q2 net loss $21.1M vs $19.7M in Q1; diluted EPS -$0.52 vs -$0.49.
R&D expenses $8.0M in Q2, down from $8.3M Q1; VTP-1000 celiac trial lead driver.
Phase 1 AVALON SAD final cohort ongoing; topline data expected early Q4 2025.
MAD portion of AVALON started July 2025; data expected mid-2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.